Guselkumab在系统性初治中重度斑块状银屑病中优于富马酸酯:POLARIS随机IIIb期试验
POLARIS是一项多中心、随机、开放标签、评估者盲法、活性对照的IIIb期试验,比较Guselkumab与富马酸酯(FAE)在系统性初治中重度斑块状银屑病患者中的疗效与安全性。
要点
- Guselkumab第24周PASI 90应答率82%,显著优于FAE的14%。
- Guselkumab组PASI 100应答率32%,FAE组仅3%。
- Guselkumab不良事件发生率73%,低于FAE的98%。
核心结论
- 在系统性初治中重度斑块状银屑病患者中,Guselkumab至第24周在疗效上优于FAE。
- Guselkumab安全性良好,不良事件发生率低于FAE,且无因不良事件停药。
研究设计与样本
- 多中心、随机、开放标签、评估者盲法、活性对照的IIIb期试验(POLARIS)。
- 纳入系统性初治中重度斑块状银屑病患者,随机接受Guselkumab 100 mg皮下注射或口服FAE(按当地标签指南)。
- Guselkumab组60例中56例完成24周治疗,FAE组59例中36例完成。
主要发现
- 不良事件发生率:Guselkumab组73% vs. FAE组98%;FAE组28%因不良事件停药,Guselkumab组无停药。
关键数值与推荐
- 不良事件发生率:Guselkumab组73% vs. FAE组98%;FAE组28%因不良事件停药,Guselkumab组0%。
临床怎么用
- 对于系统性初治的中重度斑块状银屑病患者,Guselkumab可作为优于FAE的治疗选择。
- Guselkumab在实现皮损完全清除和改善生活质量方面均显著优于FAE。
- Guselkumab的安全性优于FAE,因不良事件停药的风险更低。
局限性
- 本研究为开放标签设计,尽管评估者盲法,但患者和研究者的非盲态可能引入偏倚。
- FAE组脱落率较高(36/59完成),可能影响结果解释。
- 研究仅报告至第24周的结果,长期疗效和安全性未涉及。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guselkumab, a fully human interleukin-23 antibody, is approved for systemic treatment of patients with moderate-to-severe plaque psoriasis. OBJECTIVES: To compare the efficacy and safety of guselkumab with those of fumaric acid esters (FAE) in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment. METHODS: Eligible patients were randomized to this multicentre, randomized, open-label, assessor-blinded, active-comparator-controlled phase IIIb study to receive guselkumab 100 mg by subcutaneous injection or oral FAE according to local label guidelines. RESULTS: Through week 24, 56 of 60 patients completed guselkumab treatment and 36 of 59 completed FAE treatment. The primary endpoint (proportion of patients with ≥ 90% improvement from their baseline Psoriasis Area and Severity Index; PASI 90 response) was achieved by significantly more patients receiving guselkumab than FAE at week 24 (82% vs. 14%, P < 0·001). Analysis of the major secondary endpoints confirmed a statistically significant difference between the treatments with regards to PASI 75 response (90% vs. 27%, P < 0·001) and Dermatology Life Quality Index score of 0 or 1 (no effect at all on the patient's quality of life; 62% vs. 17%, P < 0·001). More patients in the guselkumab group achieved completely clear skin (PASI 100 response) than in the FAE group (32% vs. 3%, P < 0·001). The incidence of adverse events was lower with guselkumab than with FAE (73% vs. 98%). Overall, 28% of patients on FAE discontinued due to an adverse event, compared with none receiving guselkumab. No new safety findings were observed for guselkumab. CONCLUSIONS: Guselkumab demonstrated superiority over FAE in systemic-treatment-naive patients with moderate-to-severe plaque psoriasis through 24 weeks.
引用
- Thaçi D, Pinter A, Sebastian M, et al. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). Br J Dermatol. 2020. PMID: 31705526. doi:10.1111/bjd.18696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。